Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Stock Information for Cross Timbers Royalty Trust

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cross Timbers Royalty Trust

Moleculin Announces $5.9 Million Public Offering
Moleculin Participates in Virtual Investor "What This Means" Segment
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
Moleculin Participates in Virtual Investor "What This Means" Segment
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.